Aryl substituted hydantoin compounds and their use as sodium channel blockers
CA 2492210 A1 · Owner: Euro-Celtique S.A. · Inventors: Kyle, Donald J.; Sun, Qun
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to aryl substituted hydantoins of Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof wherein n, A, A', R, R1 and R2, are defined in the specification. The invention is also directed to the use of compounds of Formula (I) for the treatment of neuronal damage following global and focal ischemia for the treatment or prevention of , neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS) and , for the treatment, prevention or amelioration of both acute or chronic pain as antitinnitus agents, as anticonvulsants and as antimanic depressants, as , local anesthetics as antiarrhythmics and for the treatment or prevention of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 31, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.